Insightec is highlighting a study that shows the company's Exablate Prostate system is a safe and effective alternative treatment option for patients with intermediate-risk prostate cancer, according to results published June 14 in the Lancet Oncology.
The Insightec system uses focused sound waves to destroy targeted tissue in the prostate under MRI guidance to visualize patient anatomy for targeting and real-time temperature monitoring.
A team led by Dr. Behfar Ehdaie from the Memorial Sloan Kettering Cancer Center in New York treated 101 patients with the system, using MRI-guided focused ultrasound. At 24 months, 78 of 89 men had no evidence of grade group 2 or higher prostate cancer in the treated area. No grade 4 or grade 5 treatment-related adverse events were reported, and only one grade 3 adverse event was reported. The researchers also found there were no treatment-related deaths.
The Insightec Exablate Prostate system received 510(k) clearance in November 2021 from the U.S. Food and Drug Administration.
